NL-OMON52416已完成不适用
Third population-based immune surveillance study used for the evaluation of immunity against SARS-CoV-2 - Immunity against SARS-CoV-2 in Dutch population (PIENTER Corona)
RIVM0 个研究点目标入组 11,229 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 11,229
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 0 至 99（—）
入选标准
- •Subject previously participated in the PIENTER 3 study (2016/17), and had
- •indicated that they could be approached for a follow-up study, or subjects from
- •a random age-stratified sample from the Netherlands
排除标准
- •not applicable
研究者
相似试验
已完成
不适用
Third population-based immune surveillance study for the evaluation of the National Immunisation Programme in the Netherlands: the PIENTER3 studyimmune systemprotection against infectious diseases10019815NL-OMON42468RIVM8,400
招募中
不适用
Immunity against SARS-CoV-2 in Dutch populatio<p>COVID-19, SARS-CoV-2</p>NL-OMON21435ational Institute for Public Health and the Environment (RIVM)14,000
尚未招募
不适用
PIENTER-onderzoekThe age-specific seroprevalence (immunity) for diseases included in the NIP of the Dutch general populationNL-OMON24544ational Institute for Public Health and the Environment (RIVM)8,400
已完成
3 期
A study to evaluate immune non-inferiority and safety of Tetravalent Rotavirus Vaccine (BRV-TV) in comparison to licensed vaccine (RotaTeq) in healthy infants.CTRI/2014/08/004893Shantha Biotechnics Limited1,182
已完成
不适用
A prospective observational study of immune-checkpoint inhibitor (Nivolumab) treatment in patients with non-small cell lung canceron-small cell lung cancerJPRN-UMIN000021600Kitasato University School of Medicine52